Success Metrics

Clinical Success Rate
86.4%

Based on 19 completed trials

Completion Rate
86%(19/22)
Active Trials
24(35%)
Results Posted
21%(4 trials)
Terminated
3(4%)

Phase Distribution

Ph early_phase_1
15
22%
Ph phase_3
1
1%
Ph phase_2
11
16%
Ph phase_1
8
12%
Ph phase_4
3
4%
Ph not_applicable
22
32%

Phase Distribution

23

Early Stage

11

Mid Stage

4

Late Stage

Phase Distribution60 total trials
Early Phase 1First-in-human
15(25.0%)
Phase 1Safety & dosage
8(13.3%)
Phase 2Efficacy & side effects
11(18.3%)
Phase 3Large-scale testing
1(1.7%)
Phase 4Post-market surveillance
3(5.0%)
N/ANon-phased studies
22(36.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

79.2%

19 of 24 finished

Non-Completion Rate

20.8%

5 ended early

Currently Active

24

trials recruiting

Total Trials

68

all time

Status Distribution
Active(32)
Completed(19)
Terminated(5)
Other(12)

Detailed Status

Completed19
Recruiting18
unknown12
Active, not recruiting6
Enrolling by invitation4
Not yet recruiting4

Development Timeline

Analytics

Development Status

Total Trials
68
Active
24
Success Rate
86.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 115 (25.0%)
Phase 18 (13.3%)
Phase 211 (18.3%)
Phase 31 (1.7%)
Phase 43 (5.0%)
N/A22 (36.7%)

Trials by Status

recruiting1826%
unknown1218%
terminated34%
withdrawn23%
completed1928%
enrolling_by_invitation46%
not_yet_recruiting46%
active_not_recruiting69%

Recent Activity

Clinical Trials (68)

Showing 20 of 68 trialsScroll for more
NCT04457258Early Phase 1

68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma

Active Not Recruiting
NCT07712172

Assessing Granulomatosis With Polyangiitis Activity: 18F-FDG PET/CT vs BVAS v3

Completed
NCT04273555Phase 1

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

Withdrawn
NCT03173924Phase 2

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

Active Not Recruiting
NCT03181867Phase 2

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Active Not Recruiting
NCT06453915Early Phase 1

NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease

Recruiting
NCT06715020Not Applicable

Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging

Recruiting
NCT04016818Early Phase 1

Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution

Withdrawn
NCT07604207Early Phase 1

Multi-organ Imaging of Microvascular and Metabolic Function

Not Yet Recruiting
NCT06503146Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Recruiting
NCT07589101Not Applicable

5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Not Yet Recruiting
NCT07285993Phase 2

Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET

Not Yet Recruiting
NCT07553741Not Applicable

Application and Comparison of [68Ga]Ga-FAPI-04 PET, [18F]FDG PET, and Contrast-Enhanced MRI in Predicting Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Completed
NCT05876858Early Phase 1

EXPLORER Total Body PET/CT Imaging for Myofascial Pain

Active Not Recruiting
NCT06014515Early Phase 1

Single-tracer Multiparametric PET Imaging

Recruiting
NCT05436093Not Applicable

CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Recruiting
NCT05321316Not Applicable

Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma

Recruiting
NCT04459273Phase 1

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

Active Not Recruiting
NCT05641753Phase 4

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

Recruiting
NCT04147494Early Phase 1

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
68